![Yosuke Yamamoto](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Yosuke Yamamoto has held positions as an Outside Director at SoPros, Inc. and as a Partner at Universal Materials Incubator Co., Ltd.
since 2017.
Aktive Positionen von Yosuke Yamamoto
Unternehmen | Position | Beginn |
---|---|---|
Universal Materials Incubator Co., Ltd.
![]() Universal Materials Incubator Co., Ltd. Investment ManagersFinance Universal Materials Incubator Co., Ltd. (UMI) is an Independent Venture Capital firm founded in 2015. Universal Materials Incubator Co., Ltd. is headquartered in Tokyo. | Private Equity Investor | 01.04.2017 |
SoPros, Inc.
![]() SoPros, Inc. Investment ManagersFinance SoPros, Inc. is a Japanese startup company founded in May 2018 by Makoto Watanabe. The company is based in Tsukuba, Japan. SoPros aims to enter the healthcare market by utilizing high-specific micro-algae improvement technology through cutting-edge biotechnology. The company's goal is to contribute to the world healthcare by developing in-house stocks derived from oanti okitorium and micro-algae technology. The CEO is Shoichi Ikemizu. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Universal Materials Incubator Co., Ltd.
![]() Universal Materials Incubator Co., Ltd. Investment ManagersFinance Universal Materials Incubator Co., Ltd. (UMI) is an Independent Venture Capital firm founded in 2015. Universal Materials Incubator Co., Ltd. is headquartered in Tokyo. | Finance |
SoPros, Inc.
![]() SoPros, Inc. Investment ManagersFinance SoPros, Inc. is a Japanese startup company founded in May 2018 by Makoto Watanabe. The company is based in Tsukuba, Japan. SoPros aims to enter the healthcare market by utilizing high-specific micro-algae improvement technology through cutting-edge biotechnology. The company's goal is to contribute to the world healthcare by developing in-house stocks derived from oanti okitorium and micro-algae technology. The CEO is Shoichi Ikemizu. | Finance |